EIB backs development of AntibioTx anti-infective

AntibioTx A/S (Hellerup, Denmark) is to receive €20 million ($23.2 million) from a tranched financing with the European Investment Bank to support Phase II and Phase III development of lead candidate ATx201 to treat skin infections.

Co-founder and CEO Rasmus Toft-Kehler told BioCentury that AntibioTx has now raised about $45 million total, but declined to name investors or the terms of the new financing. Toft-Kehler said the company has received the first of two tranches in the EIB fund raise...